Johnson & Johnson (NYSE:JNJ) Shares Purchased by Camarda Financial Advisors LLC
Camarda Financial Advisors LLC lifted its position in Johnson & Johnson (NYSE:JNJ) by 403.5% in the 1st quarter, HoldingsChannel.com reports. The firm owned 7,643 shares of the company’s stock after acquiring an additional 6,125 shares during the quarter. Johnson & Johnson comprises about 5.1% of Camarda Financial Advisors LLC’s portfolio, making the stock its 6th biggest holding. Camarda Financial Advisors LLC’s holdings in Johnson & Johnson were worth $1,002,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Norges Bank acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $4,139,107,000. Amundi Pioneer Asset Management Inc. lifted its stake in shares of Johnson & Johnson by 77.4% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 4,725,664 shares of the company’s stock valued at $689,332,000 after purchasing an additional 2,061,958 shares during the period. M&G Investment Management Ltd. acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $269,234,000. Alliancebernstein L.P. lifted its stake in shares of Johnson & Johnson by 20.5% in the 4th quarter. Alliancebernstein L.P. now owns 9,399,325 shares of the company’s stock valued at $1,371,080,000 after purchasing an additional 1,599,581 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Johnson & Johnson by 3.7% in the 4th quarter. Geode Capital Management LLC now owns 38,393,079 shares of the company’s stock valued at $5,589,167,000 after purchasing an additional 1,364,028 shares during the period. Hedge funds and other institutional investors own 67.66% of the company’s stock.
In related news, Director William D. Perez bought 500 shares of the firm’s stock in a transaction on Friday, March 13th. The shares were bought at an average price of $127.69 per share, with a total value of $63,845.00. Following the completion of the transaction, the director now directly owns 16,030 shares of the company’s stock, valued at approximately $2,046,870.70. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.27% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 14th. The company reported $2.30 EPS for the quarter, beating the Zacks’ consensus estimate of $2.03 by $0.27. Johnson & Johnson had a net margin of 24.47% and a return on equity of 39.71%. The company had revenue of $20.69 billion for the quarter, compared to analysts’ expectations of $19.48 billion. During the same quarter in the prior year, the company posted $2.10 earnings per share. Johnson & Johnson’s revenue for the quarter was up 3.3% compared to the same quarter last year. As a group, analysts anticipate that Johnson & Johnson will post 7.68 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be given a $1.01 dividend. The ex-dividend date of this dividend is Friday, May 22nd. This represents a $4.04 dividend on an annualized basis and a yield of 2.80%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.95. Johnson & Johnson’s dividend payout ratio is presently 43.78%.
Several research firms recently issued reports on JNJ. Bank of America upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their target price for the company from $150.00 to $175.00 in a research note on Wednesday, April 22nd. SVB Leerink cut their price target on shares of Johnson & Johnson from $172.00 to $160.00 and set an “outperform” rating for the company in a report on Wednesday, April 8th. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $160.00 to $170.00 and gave the stock an “overweight” rating in a report on Wednesday, April 29th. UBS Group lowered shares of Johnson & Johnson from a “buy” rating to a “neutral” rating and cut their price target for the stock from $163.00 to $160.00 in a report on Tuesday, April 28th. Finally, Citigroup boosted their price target on shares of Johnson & Johnson from $150.00 to $165.00 and gave the stock a “buy” rating in a report on Wednesday, April 15th. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $163.47.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: Discount Rate
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.